Search Results - "Engstler, Barbara Schacher"

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway by Dafflon, Caroline, Gaulis, Swann, Barys, Louise, Kapur, Karen, Cornacchione, Vanessa, Schukur, Lina, Bergling, Sebastian, Traggiai, Elisabetta, Jansky, Selina, Hellmann, Leon, Engstler, Barbara Schacher, Kerr, Grainne, de Weck, Antoine, Ruddy, David A, Naumann, Ulrike, Stauffer, Frédéric, Gaul, Christoph, Lin, Ying, Billy, Eric, Weiss, Andreas, Hofmann, Francesco, Ito, Moriko, Tiedt, Ralph

“…The histone 3 lysine 79 (H3K79) methyltransferase (HMT) DOT1L is known to play a critical role for growth and survival of -rearranged leukemia. Serendipitous…”
Get full text

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation by Baltschukat, Sabrina, Engstler, Barbara Schacher, Huang, Alan, Hao, Huai-Xiang, Tam, Angela, Wang, Hui Qin, Liang, Jinsheng, DiMare, Matthew T, Bhang, Hyo-Eun Carrie, Wang, Youzhen, Furet, Pascal, Sellers, William R, Hofmann, Francesco, Schoepfer, Joseph, Tiedt, Ralph

“…The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the…”
Get full text

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma by Goyal, Lipika, Saha, Supriya K, Liu, Leah Y, Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G, Lennerz, Jochen K, Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E, Gurski, Jr, Joseph M, Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P, Stone, James R, Iafrate, A John, Getz, Gad, Porta, Diana Graus, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B, Bardeesy, Nabeel, Zhu, Andrew X

“…Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic…”
Get more information

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models by Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G, Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R, Caponigro, Giordano

“…Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6…”
Get full text

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors by Tiedt, Ralph, King, Frederick J., Stamm, Christelle, Niederst, Matthew J., Delach, Scott, Zumstein-Mecker, Sabine, Meltzer, Jodi, Mulford, Iain J., Labrot, Emma, Engstler, Barbara Schacher, Baltschukat, Sabrina, Kerr, Grainne, Golji, Javad, Wyss, Daniel, Schnell, Christian, Ainscow, Edward, Engelman, Jeffrey A., Sellers, William R., Barretina, Jordi, Caponigro, Giordano, Porta, Diana Graus

“…Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not…”
Get full text

Abstract 2346: Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib by Tiedt, Ralph, Delach, Scott, Kovats, Steven, Horn, Thomas, Acker, Michael, Engstler, Barbara Schacher, Caponigro, Giordano, Su, Fei

“…Abstract A hallmark of cancer is unchecked cell division. Retinoblastoma protein (Rb) is a human tumor suppressor that guards a cell’s entry into S phase by…”
Get full text

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models by Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G, Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R, Caponigro, Giordano

“…[This corrects the article DOI: 10.18632/oncotarget.26215.]…”
Get full text

Abstract LB222: Elucidating the cellular responses and mechanism of action of 177Lu-based radioligand therapy by Ranzani, Marco, Hindupur, Sravanth, Cicconi, Alessandro, Sastre-Moreno, Guillermo, Kristian, Alexander, Engstler, Barbara Schacher, Pinch, Benika, Hartnagel, Charlene, Gorses, Delphine, Simon, Elise, Mandon, Emeline, Schramm, Emilien, Schaeffer, Fanny, Reber, Josefine, Barys, Louise, Deberle, Luisa, Walter, Milene, Bessey, Ralph, Destefani, Riccardo, Miot, Xavier, Elinati, Elias, Shao, Nan, Boursier, Marie, Barlow, Joseph, Thapa, Asmita, Galbiati, Alessandro, Grande, Diego, Rajendra, Eeson, Martin, Niall, Smith, Graeme, Schmelzle, Tobias, Reschke, Markus, Robinson, Helen, Cortes-Cros, Marta

“…Abstract Radioligand therapy (RLT) is emerging as a safe and effective targeted approach for treating several types of cancers. Lutathera® (177Lu-Dotatate) and…”
Get full text